Y-maBs Therapeutics Class Action Lawsuit Announced: Johnson
SAN DIEGO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on...
Source: globenewswire.com
📰 Y Mabs News
Y Mabs News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Y Mabs. Real-time updates on events, politics, business and more.
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) Investor Update:
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is continuing its investigation of claims on behalf of...
Source: globenewswire.com
Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
Q3 2022 DANYELZA® record product revenues of $12.5 million, YoY growth of 40% and 28% sequential increase compared to Q2 2022 DANYELZA marketing authorization
New York United States Adium Pharma Globe Newswirey Mabs Therapeutics Inc Oncologic Drugs Advisory Committee International Society Of Pediatric Oncology
Source: einnews.com
Y-mAbs Therapeutics Investigated by Block & Leviton For
BOSTON , Oct. 26, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for potential securities law...
United States Y Mabs Therapeutics Inc Drug Administration Block Leviton Y Mabs Therapeutics Biologics License Application
Source: globenewswire.com
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel,
New York United States Globe Newswirey Mabs Therapeutics Inc Us Federal Drug Administration Brazilian Health Regulatory Agency Y Mabs Therapeutics Inc
Source: einnews.com